Daiichi Sankyo

Zymeworks, Daiichi end $293M bispecific collab after 6 unfruitful years
Zymeworks, Daiichi end $293M bispecific collab after 6 unfruitful years
Fierce Biotech
Zymeworks
Daiichi Sankyo
immuno-oncology
biobucks
Flag link:
Daiichi torches Esperion’s Nexletol milestone promises
Daiichi torches Esperion’s Nexletol milestone promises
EP Vantage
Daiichi Sankyo
Esperion Therapeutics
Nexletol
Flag link:
AstraZeneca, Daiichi Sankyo tease new Enhertu data — but details remain under wraps
AstraZeneca, Daiichi Sankyo tease new Enhertu data — but details remain under wraps
Endpoints
AstraZeneca
Daiichi Sankyo
Enhertu
clinical trials
Flag link:
Daiichi Sankyo gets US patent office to restart review of Seagen patent
Daiichi Sankyo gets US patent office to restart review of Seagen patent
Endpoints
Daiichi Sankyo
Seagen
PTO
patents
Flag link:
Daiichi Sankyo to build Japan's first mRNA vaccine manufacturing facility — report
Daiichi Sankyo to build Japan's first mRNA vaccine manufacturing facility — report
Endpoints
Daiichi Sankyo
Japan
MRNA
vaccines
drug manufacturing
Flag link:
The first big test for the son of Enhertu
The first big test for the son of Enhertu
EP Vantage
Daiichi Sankyo
Enhertu
datopotamab deruxtecan
clinical trials
Flag link:
Biopharma's stock market winners of 2022 revealed
Biopharma's stock market winners of 2022 revealed
EP Vantage
pharma stocks
Merck
Eli Lilly
AbbVie
Daiichi Sankyo
Vertex Pharmaceuticals
Takeda
Sarepta Therapeutics
Halozyme
Horizon Therapeutics
Flag link:
10 clinical trials to watch in the first half of 2023
10 clinical trials to watch in the first half of 2023
BioPharma Dive
clinical trials
Alzheimer's disease
obesity
Huntington's disease
M&A
AstraZeneca
Daiichi Sankyo
Nimbus Therapeutics
Takeda
Eli Lilly
Sanofi
Regeneron
Moderna Therapeutics
Gilead Sciences
Pfizer
Roivant
Alnylam
uniQure
Flag link:
Biotech’s key upcoming clinical results
Biotech’s key upcoming clinical results
EP Vantage
clinical trials
Acadia Pharmaceuticals
Argenx
Arrowhead Pharmaceuticals
Biomarin
BioNTech
Daiichi Sankyo
Day One
EQRx
Fate Therapeutics
FibroGen
Gilead Sciences
Idorsia
Immunogen
Intellia Therapeutics
Karuna Therapeutics
Moderna Therapeutics
Regeneron
Roche
Travere Therapeutics
Vaxcyte
Flag link:
Big pharma’s new year catalysts
Big pharma’s new year catalysts
EP Vantage
AstraZeneca
Daiichi Sankyo
Pfizer
Roche
CSL
uniQure
Novo Nordisk
Eli Lilly
Flag link:
AstraZeneca-Daiichi Sankyo’s therapy shows response in breast cancer trials
AstraZeneca-Daiichi Sankyo’s therapy shows response in breast cancer trials
Clinical Trials Arena
AstraZeneca
Daiichi Sankyo
clinical trials
datopotamab deruxtecan
metastatic triple-negative breast cancer
breast cancer
Flag link:
SABCS: AZ writes the 'next chapter' in Enhertu's saga with head-to-head win versus Roche's Kadcyla
SABCS: AZ writes the 'next chapter' in Enhertu's saga with head-to-head win versus Roche's Kadcyla
Fierce Pharma
SABCS
AstraZeneca
Enhertu
breast cancer
Daiichi Sankyo
Roche
Kadcyla
Flag link:
Chasing Gilead, AstraZeneca-Daiichi lay down phase 2 breast cancer data for antibody-drug conjugate
Chasing Gilead, AstraZeneca-Daiichi lay down phase 2 breast cancer data for antibody-drug conjugate
Fierce Biotech
AstraZeneca
Daiichi Sankyo
breast cancer
antibody-drug conjugate
clinical trials
Gilead Sciences
Flag link:
Daiichi Sankyo To Transfer Yescarta Marketing Authorization In Japan To Gilead Sciences
Daiichi Sankyo To Transfer Yescarta Marketing Authorization In Japan To Gilead Sciences
NASDAQ.com
Daiichi Sankyo
Gilead Sciences
Yescarta
Japan
Flag link:
The problem with Her2-low testing
The problem with Her2-low testing
EP Vantage
AstraZeneca
Daiichi Sankyo
Enhertu
breast cancer
diagnostics
HER2-low breast cancer
Flag link:
Cancer drugmaker Plexxikon gets new life as Opna Bio
Cancer drugmaker Plexxikon gets new life as Opna Bio
BioPharma Dive
Plexxikon
Opna Bio
rebranding
oncology
Daiichi Sankyo
Flag link:
Daiichi Sankyo’s Covid-19 vaccine trial meets primary endpoint
Daiichi Sankyo’s Covid-19 vaccine trial meets primary endpoint
Clinical Trials Arena
Daiichi Sankyo
clinical trials
MRNA
vaccines
DS-5670
COVID-19
Flag link:
After nearly 20 years, Cyclacel kicks phase 3 leukemia drug back to Daiichi
After nearly 20 years, Cyclacel kicks phase 3 leukemia drug back to Daiichi
Fierce Biotech
Cyclacel
AML
Sapacitabine
Daiichi Sankyo
Flag link:
Daiichi Sankyo sets new highs for AstraZeneca-partnered cancer drug Enhertu
Daiichi Sankyo sets new highs for AstraZeneca-partnered cancer drug Enhertu
Endpoints
Daiichi Sankyo
AstraZeneca
Enhertu
breast cancer
non-small cell lung cancer
Flag link:
FDA grants priority review for Daiichi Sankyo’s AML medicine
FDA grants priority review for Daiichi Sankyo’s AML medicine
Pharmaceutical Business Review
FDA
priority review
Daiichi Sankyo
quizartinib
acute myeloid leukemia
Flag link:

Pages